Vivesto AB (VIVE.ST)
SEK 0.27
(-1.45%)
SEK 0.27
(-1.45%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 30.45 Million SEK | -31.71% |
| 2021 | 44.59 Million SEK | -74.78% |
| 2020 | 176.8 Million SEK | -4.92% |
| 2019 | 185.95 Million SEK | -16.36% |
| 2018 | 222.33 Million SEK | -0.32% |
| 2017 | 223.03 Million SEK | 0.83% |
| 2016 | 221.21 Million SEK | 16.72% |
| 2015 | 189.52 Million SEK | 36.49% |
| 2014 | 138.85 Million SEK | -25.54% |
| 2013 | 186.47 Million SEK | 47.97% |
| 2012 | 126.02 Million SEK | 65.1% |
| 2011 | 76.33 Million SEK | 191.93% |
| 2010 | 26.14 Million SEK | -30.91% |
| 2009 | 37.84 Million SEK | 5.45% |
| 2008 | 35.89 Million SEK | 57.01% |
| 2007 | 22.86 Million SEK | 117.8% |
| 2006 | 10.49 Million SEK | 118.84% |
| 2005 | 4.79 Million SEK | 2.9% |
| 2004 | 4.66 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 30.13 Million SEK | 18.89% |
| 2023 Q1 | 25.34 Million SEK | -16.76% |
| 2022 Q2 | 34.3 Million SEK | -21.58% |
| 2022 Q4 | 30.45 Million SEK | 9.77% |
| 2022 FY | 30.45 Million SEK | -31.71% |
| 2022 Q3 | 27.74 Million SEK | -19.14% |
| 2022 Q1 | 43.75 Million SEK | -1.89% |
| 2021 Q3 | 141.23 Million SEK | -20.93% |
| 2021 Q2 | 178.61 Million SEK | -3.01% |
| 2021 FY | 44.59 Million SEK | -74.78% |
| 2021 Q1 | 184.16 Million SEK | 4.16% |
| 2021 Q4 | 44.59 Million SEK | -68.42% |
| 2020 Q2 | 173.97 Million SEK | -6.44% |
| 2020 Q4 | 176.8 Million SEK | -12.32% |
| 2020 FY | 176.8 Million SEK | -4.92% |
| 2020 Q3 | 201.64 Million SEK | 15.9% |
| 2020 Q1 | 185.95 Million SEK | 20.92% |
| 2019 Q4 | 153.78 Million SEK | -20.31% |
| 2019 Q1 | 222.33 Million SEK | 36.0% |
| 2019 FY | 185.95 Million SEK | -16.36% |
| 2019 Q2 | 241.18 Million SEK | 8.48% |
| 2019 Q3 | 192.98 Million SEK | -19.98% |
| 2018 Q3 | 197.97 Million SEK | -8.76% |
| 2018 Q4 | 163.48 Million SEK | -17.42% |
| 2018 Q2 | 216.97 Million SEK | -2.72% |
| 2018 FY | 222.33 Million SEK | -0.32% |
| 2018 Q1 | 223.03 Million SEK | 12.05% |
| 2017 FY | 223.03 Million SEK | 0.83% |
| 2017 Q4 | 199.05 Million SEK | 13.2% |
| 2017 Q3 | 175.83 Million SEK | -18.94% |
| 2017 Q2 | 216.91 Million SEK | -1.94% |
| 2017 Q1 | 221.21 Million SEK | 1.17% |
| 2016 Q1 | 189.52 Million SEK | 10.26% |
| 2016 FY | 221.21 Million SEK | 16.72% |
| 2016 Q4 | 218.65 Million SEK | -3.22% |
| 2016 Q3 | 225.92 Million SEK | -0.6% |
| 2016 Q2 | 227.28 Million SEK | 19.92% |
| 2015 Q2 | 154.2 Million SEK | 11.05% |
| 2015 Q4 | 171.88 Million SEK | -5.04% |
| 2015 Q1 | 138.85 Million SEK | 3.64% |
| 2015 FY | 189.52 Million SEK | 36.49% |
| 2015 Q3 | 181 Million SEK | 17.38% |
| 2014 Q1 | 186.47 Million SEK | 864.85% |
| 2014 Q4 | 133.98 Million SEK | -29.25% |
| 2014 Q3 | 189.38 Million SEK | 0.07% |
| 2014 Q2 | 189.26 Million SEK | 1.5% |
| 2014 FY | 138.85 Million SEK | -25.54% |
| 2013 Q1 | 126.02 Million SEK | 796.15% |
| 2013 FY | 186.47 Million SEK | 47.97% |
| 2013 Q3 | 125.25 Million SEK | 0.11% |
| 2013 Q4 | 19.32 Million SEK | -84.57% |
| 2013 Q2 | 125.12 Million SEK | -0.71% |
| 2012 Q1 | 76.33 Million SEK | 167.5% |
| 2012 Q4 | 14.06 Million SEK | -90.07% |
| 2012 FY | 126.02 Million SEK | 65.1% |
| 2012 Q2 | 118.61 Million SEK | 55.39% |
| 2012 Q3 | 141.68 Million SEK | 19.45% |
| 2011 Q3 | 3.56 Million SEK | -87.64% |
| 2011 Q2 | 28.84 Million SEK | 10.3% |
| 2011 Q4 | 28.53 Million SEK | 700.22% |
| 2011 FY | 76.33 Million SEK | 191.93% |
| 2011 Q1 | 26.14 Million SEK | 3.27% |
| 2010 Q4 | 25.31 Million SEK | -75.93% |
| 2010 FY | 26.14 Million SEK | -30.91% |
| 2010 Q3 | 105.2 Million SEK | 63.31% |
| 2010 Q2 | 64.41 Million SEK | 70.21% |
| 2010 Q1 | 37.84 Million SEK | 0.0% |
| 2009 FY | 37.84 Million SEK | 5.45% |
| 2008 FY | 35.89 Million SEK | 57.01% |
| 2007 FY | 22.86 Million SEK | 117.8% |
| 2006 FY | 10.49 Million SEK | 118.84% |
| 2005 FY | 4.79 Million SEK | 2.9% |
| 2004 FY | 4.66 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AcuCort AB | 10.97 Million SEK | -177.467% |
| AlzeCure Pharma AB (publ) | 8.22 Million SEK | -270.147% |
| BioGaia AB (publ) | 302.84 Million SEK | 89.945% |
| Enzymatica AB (publ) | 49.3 Million SEK | 38.234% |
| Enorama Pharma AB (publ) | 14.84 Million SEK | -105.105% |
| Gabather AB (publ) | 6.87 Million SEK | -342.745% |
| Klaria Pharma Holding AB (publ.) | 31.98 Million SEK | 4.796% |
| Moberg Pharma AB (publ) | 24 Million SEK | -26.846% |
| Nanexa AB (publ) | 36.42 Million SEK | 16.403% |
| Newbury Pharmaceuticals AB (publ) | 38.95 Million SEK | 21.826% |
| ODI Pharma AB | 10.05 Million SEK | -202.774% |
| Orexo AB (publ) | 727.7 Million SEK | 95.815% |
| Probi AB (publ) | 181.31 Million SEK | 83.205% |
| Swedencare AB (publ) | 2.31 Billion SEK | 98.685% |
| Swedish Orphan Biovitrum AB (publ) | 40.16 Billion SEK | 99.924% |
| Toleranzia AB | 6.9 Million SEK | -340.758% |